Gilead Sciences (GILD) Net Income (2009 - 2026)
Gilead Sciences' (GILD) quarterly Net Income came in at -$10.5 billion in Q2 2026, down 635.24% on a YoY basis from $2.0 billion in Q2 2025, and down 619.35% quarter-over-quarter from $2.0 billion in Q1 2026.
Analysis
Gilead Sciences (GILD) Net Income (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Net Income for 18 consecutive years, with -$10.5 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Income fell 635.24% year-over-year to -$10.5 billion; the trailing twelve-month figure through Jun 2026 stood at -$2.9 billion (down 145.87% YoY), and the FY2025 full-year result was $8.5 billion, up 1676.62% from the prior year.
- Net Income slipped to -$10.5 billion in Q2 2026 per GILD's latest filing, from $2.0 billion in the prior quarter.
- Across five years, Net Income topped out at $3.1 billion in Q3 2025 and bottomed at -$10.5 billion in Q2 2026.
- Historically, Net Income has averaged $613.2 million across 5 years, with a median of $1.5 billion in 2023.
- The sharpest annual moves came in 2023 and 2026: Net Income surged 8100.0% in 2023, then slumped 635.24% in 2026.
- Over 5 years, Net Income stood at $1.6 billion in 2022, then fell by 13.29% to $1.4 billion in 2023, then grew by 25.85% to $1.8 billion in 2024, then surged by 41.86% to $2.5 billion in 2025, then tumbled by 515.19% to -$10.5 billion in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$10.5 billion, $2.0 billion, and $2.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | -13.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.50 Bn |
| Mar 31, 2026 | 2.02 Bn |
| Dec 31, 2025 | 2.53 Bn |
| Sep 30, 2025 | 3.05 Bn |
| Jun 30, 2025 | 1.96 Bn |
| Mar 31, 2025 | 1.32 Bn |
| Dec 31, 2024 | 1.78 Bn |
| Sep 30, 2024 | 1.25 Bn |
| Jun 30, 2024 | 1.62 Bn |
| Mar 31, 2024 | -4.17 Bn |
| Dec 31, 2023 | 1.42 Bn |
| Sep 30, 2023 | 2.17 Bn |
| Jun 30, 2023 | 1.04 Bn |
| Mar 31, 2023 | 984.00 Mn |
| Dec 31, 2022 | 1.63 Bn |
| Sep 30, 2022 | 1.79 Bn |
| Jun 30, 2022 | 1.14 Bn |
| Mar 31, 2022 | 12.00 Mn |
| Dec 31, 2021 | 376.00 Mn |
| Sep 30, 2021 | 2.59 Bn |